Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated ...
NYU Langone-led international study featured at ACC.26 supports combining advanced imaging to guide diagnosis and care ...